8-K: RxSight Reports Strong Q3 2024 Results, Raises Full-Year Guidance

RxSight, Inc. announced a 59% increase in revenue for the third quarter of 2024, driven by strong sales of its Light Adjustable Lenses and Light Delivery Devices, and raised its full-year revenue guidance.

Summary

• RxSight reported a 59% increase in revenue for the third quarter of 2024, reaching $35.3 million, compared to $22.2 million in the same period last year.
• The company sold 24,554 Light Adjustable Lenses (LAL/LAL+), an 80% increase in procedure volume year-over-year.
• Sales of Light Delivery Devices (LDDs) increased by 18% to 78 units, expanding the installed base to 888 LDDs, a 51% increase year-over-year.
• Gross profit for the quarter was $25.2 million, or 71.4% of revenue, up from $13.7 million, or 61.9% of revenue, in the third quarter of 2023.
• The company's net loss for the quarter was $(6.3) million, or $(0.16) per share, compared to a net loss of $(12.4) million, or $(0.35) per share, in the third quarter of 2023.
• Adjusted net earnings for the quarter were $214 thousand, or $0.00 per diluted share, compared to an adjusted net loss of $(6.9) million, or $(0.19) per share, in the third quarter of 2023.
• RxSight raised its full-year 2024 revenue guidance to the top of its previous range, between $139.0 million and $140.0 million, representing approximately 57% growth compared to 2023.
• The company also increased its gross margin guidance to 70% to 71% and lowered its operating expense guidance to the low end of the previous range of $135.0 to $136.0 million.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, improved profitability, and raised guidance. The company's performance is clearly trending in a positive direction, indicating a strong outlook.

Positives

• The company experienced significant revenue growth, driven by increased sales of both LALs and LDDs.
• The substantial increase in LAL procedure volume indicates strong market adoption of the technology.
• The expansion of the LDD installed base demonstrates the company's growing market presence.
• Improved gross profit margins reflect better cost management and pricing stability.
• The company's revised full-year guidance indicates confidence in continued growth and profitability.
• The reduction in net loss and the achievement of adjusted net earnings are positive indicators of financial improvement.

Negatives

• The company still reported a net loss of $(6.3) million for the quarter, although this is an improvement from the previous year.
• Operating expenses increased by 31% year-over-year, although this was on a 59% increase in revenue.

Risks

• The company's future performance is subject to various risks, including the ability to maintain cash balances and successfully commercialize products.
• The company's forward-looking statements are based on current expectations and are subject to change due to various factors.
• The company's actual results may differ materially from the forward-looking statements due to various risks and uncertainties.

Future Outlook

The company expects full-year 2024 revenue to be at the top of its previous guidance range, between $139.0 million and $140.0 million, with gross margin between 70% and 71% and operating expenses at the low end of the previous range of $135.0 to $136.0 million.

Management Comments

• Dr. Ron Kurtz, Chief Executive Officer and President, stated that the company is pleased to report another strong quarter driven by ongoing demand and enthusiasm for the RxSight system.
• Dr. Kurtz believes the third-quarter results position the company for a strong finish to 2024 and for continued success in the years to come.

Industry Context

The results indicate a strong market reception for RxSight's adjustable lens technology in the ophthalmic medical device sector, suggesting a growing trend towards customized vision solutions following cataract surgery. This is a competitive market with other IOL manufacturers, but RxSight's unique adjustability feature appears to be gaining traction.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, the 59% revenue growth and 80% increase in LAL procedure volume are strong indicators of market share gains compared to traditional IOL manufacturers.
• Companies like Alcon, Johnson & Johnson Vision, and Bausch + Lomb are major players in the IOL market, and RxSight's growth suggests it is successfully competing with these established companies.
• The gross margin of 71.4% is also a positive sign, indicating efficient operations and pricing power, which is comparable to other successful medical device companies.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and raised guidance.
• Employees may benefit from the company's growth and success.
• Customers (doctors and patients) will benefit from the continued availability of the RxSight system.
• Suppliers may see increased demand for their products and services.

Next Steps

• The company will host a conference call on November 7, 2024, to discuss the third quarter 2024 financial results.
• The company will continue to focus on growing its LDD installed base and supporting increased LAL sales volume.

Key Dates

Keywords

RxSight, Light Adjustable Lens, Light Delivery Device, Ophthalmic Medical Device, Cataract Surgery, Financial Results, Revenue Growth, Gross Margin, Adjusted Net Earnings, Guidance